Skip to main content

Table 1 Yerelon cohort patient who initiated antiretroviral study participants baseline characteristics

From: Immunovirological discordance among female sex workers who start antiretroviral therapy in Burkina Faso

Variable at ART initiation

All Patients (n = 123)

n (%)

Patients with HIV-1 RNA suppressed at 12 months on ART

(VL < 1000 copies/mL)

(n = 105)

n (%)

Immunologic responder at 12 months on ART

(CD4 + T cell recovery ≥ 100 cells)

(n = 86)

n (%)

Patients with immunovirological discordance at 12 months

(n = 25)

n (%)

Age: median (IQR) years

33.00 (29.00–39.17)

33.02 (30.01–39.02)

32.93 (28.5–38.80)

33.00 (31.00–39.23)

 < 30

31 (25.20)

25 (23.81)

23 (26.74)

4 (16.00)

 30–39

65 (52.85)

58 (55.24)

46 (53.49)

15 (60.00)

 ≥ 40

27 (21.95)

22 (20.95)

17 (19.77)

6 (24.00)

Education level

    

 None

52 (42.28)

45 (42.86)

38 (44.19)

9 (36.00)

 Primary school

36 (29.27)

31 (29.52)

23 (26.74)

11 (44.)

 Secondary school

35 (28.45

29 (27.62)

25 (29.07)

5 (20.00)

Marital status (couple life)

    

 Yes

29 (23.58)

23 (21.90)

21 (24.42)

4 (16.00)

 No

94 (76.42)

82 (78.10)

65 (75.58)

21 (8400)

WHO clinical stage

    

 1

17 (13.82)

13 (12.38)

12 (13.95)

3 (12.00)

 2

42 (34.15)

35 (33.33)

29 (33.72)

8 (32.00)

 3 and 4

64 (52.03)

57 (54.29)

45 (52.33)

14 (56.00)

Body mass index: median (IQR)

20.60 (18.55–22.72)

20.58 (18.13–22.55)

20.38 (18.24–22.37)

20.76 (18.55–23.51)

 < 18,5

29 (23.58)

28 (26.67)

23 (26.74)

6 (24.00)

 18,5–25

83 (67.48)

67 (63.81)

57 (66.28)

15 (60.00)

 > 25

11 (8.94)

10 (9.52)

6 (6.98)

4 (16.00)

CD4 + T cell count at ART initiation:

Median (IQR)

147 (79–200)

139 (74–200)

136 (75–192)

238 (100–384)

 < 200

90 (73.17)

77 (73.33)

70 (81.40)

11 (44.00)

 200–349

23 (18.70)

19 (18.10)

14 (16.28)

7 (28.00)

 350 -500

10 (8.13)

9 (8.57)

2 (2.33)

7 (28.00)

HIV-1 Viral load (log 10copies/ml): median (IQR) (n = 52)

5.20 (4.82–5.52)

5.26 (4.85–5.58)

5.18 (4.82–5.54)

5.43 (5.28–5.65)

 < 3 log10

2 (3.85)

2 (4.17)

2 (4.76)

-

 3–5 log10

16 (30.77)

13 (27.08)

13 (30.95)

1 (12.50)

 > 5log10

34 (65.38)

33 (68.75)

27 (64.29)

7 (87.50)

ART NNRTIs initiated

    

 Nevirapine

38 (30.89)

30 (28.57)

28 (32.56)

5 (20.00)

 Efavirenz

83 (67.48)

73 (69.52)

56 (65.12)

20 (80.00)

 Protease inibitor

2 (1.63)

2 (1.90)

2 (2.33)

 

ART NRTIs initiated

    

 Tenofovir

18 (14.63)

15 (14.29)

11 (12.79)

6 (24.00)

 Zidovudine

73 (59.35)

64 (60.95)

49 (56.98)

17 (68.00)

 Stavudine

32 (26.02)

26 (24.76)

26 (30.23)

2 (8.00)

ART Adherence: median (IQR)

97.00 (92.5–99.40

97.00 (93.5–99.65)

97.00 (92.00–99.40)

96.40 (95.30–100)

 < 95%

45 (36.59)

37 (35.24)

35 (40.70)

6 (24)

 ≥ 95%

78 (63.41)

68 (64.76)

51 (59.30)

19 (76)

  1. ART antiretroviral therapy, IQR interquartile range, NNRTIs non-nucleoside reverse transcriptase inhibitors, NRTIs nucleoside/nucleotide reverse transcriptase inhibitors